Clarity Pharmaceuticals Ltd
OTC:CLRPF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (10.7), the stock would be worth $-2.7 (218% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -9.1 | $2.29 |
0%
|
| Industry Average | 10.7 | $-2.7 |
-218%
|
| Country Average | 16.5 | $-4.15 |
-281%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$945.6m
|
/ |
Jan 2026
AU$-96m
|
= |
|
|
$945.6m
|
/ |
Jun 2026
AU$-96.9m
|
= |
|
|
$945.6m
|
/ |
Jun 2027
AU$-107.6m
|
= |
|
|
$945.6m
|
/ |
Jun 2028
AU$33.6m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
C
|
Clarity Pharmaceuticals Ltd
OTC:CLRPF
|
1.1B USD | -9.1 | -11.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28.4 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.5 | 25.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.6 | 19.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 16.5 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
